622 related articles for article (PubMed ID: 34724386)
1. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD; Nastoupil LJ; Adkins S; Lacchetti C; Schneider BJ; Anadkat M; Atkins MB; Brassil KJ; Caterino JM; Chau I; Davies MJ; Ernstoff MS; Fecher L; Funchain P; Jaiyesimi I; Mammen JS; Naidoo J; Naing A; Phillips T; Porter LD; Reichner CA; Seigel C; Song JM; Spira A; Suarez-Almazor M; Swami U; Thompson JA; Vikas P; Wang Y; Weber JS; Bollin K; Ghosh M
J Clin Oncol; 2021 Dec; 39(35):3978-3992. PubMed ID: 34724386
[TBL] [Abstract][Full Text] [Related]
2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR; Lacchetti C; Schneider BJ; Atkins MB; Brassil KJ; Caterino JM; Chau I; Ernstoff MS; Gardner JM; Ginex P; Hallmeyer S; Holter Chakrabarty J; Leighl NB; Mammen JS; McDermott DF; Naing A; Nastoupil LJ; Phillips T; Porter LD; Puzanov I; Reichner CA; Santomasso BD; Seigel C; Spira A; Suarez-Almazor ME; Wang Y; Weber JS; Wolchok JD; Thompson JA;
J Clin Oncol; 2018 Jun; 36(17):1714-1768. PubMed ID: 29442540
[TBL] [Abstract][Full Text] [Related]
3. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
4. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider BJ; Naidoo J; Santomasso BD; Lacchetti C; Adkins S; Anadkat M; Atkins MB; Brassil KJ; Caterino JM; Chau I; Davies MJ; Ernstoff MS; Fecher L; Ghosh M; Jaiyesimi I; Mammen JS; Naing A; Nastoupil LJ; Phillips T; Porter LD; Reichner CA; Seigel C; Song JM; Spira A; Suarez-Almazor M; Swami U; Thompson JA; Vikas P; Wang Y; Weber JS; Funchain P; Bollin K
J Clin Oncol; 2021 Dec; 39(36):4073-4126. PubMed ID: 34724392
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
7. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
8. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
Cook J; Litzow M
Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
[TBL] [Abstract][Full Text] [Related]
9. Long-term survivorship care after CAR-T cell therapy.
Puckrin R; Jamani K; Jimenez-Zepeda VH
Eur J Haematol; 2024 Jan; 112(1):41-50. PubMed ID: 37767547
[TBL] [Abstract][Full Text] [Related]
10. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
11. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
12. How I treat refractory CRS and ICANS after CAR T-cell therapy.
Jain MD; Smith M; Shah NN
Blood; 2023 May; 141(20):2430-2442. PubMed ID: 36989488
[TBL] [Abstract][Full Text] [Related]
13. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
14. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
15. Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
Hays P; Costello C; Asudani D
Future Oncol; 2019 Dec; 15(36):4235-4246. PubMed ID: 31773980
[TBL] [Abstract][Full Text] [Related]
16. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.
Shalabi H; Gust J; Taraseviciute A; Wolters PL; Leahy AB; Sandi C; Laetsch TW; Wiener L; Gardner RA; Nussenblatt V; Hill JA; Curran KJ; Olson TS; Annesley C; Wang HW; Khan J; Pasquini MC; Duncan CN; Grupp SA; Pulsipher MA; Shah NN
Nat Rev Clin Oncol; 2021 Jun; 18(6):363-378. PubMed ID: 33495553
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
18. ASCO releases guideline on CAR T-cell therapy: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities.
O'Rourke K
Cancer; 2022 Feb; 128(3):429-430. PubMed ID: 35050523
[No Abstract] [Full Text] [Related]
19. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P
Lancet Oncol; 2023 Jun; 24(6):e255-e269. PubMed ID: 37269857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
